UK markets close in 5 hours 6 minutes

Mereo BioPharma Group plc (MREO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.9900+0.1600 (+4.18%)
At close: 04:00PM EDT
4.2000 +0.21 (+5.26%)
Pre-market: 05:35AM EDT

Mereo BioPharma Group plc

One Cavendish Place
4th Floor
London W1G 0QF
United Kingdom
44 33 3023 7300
https://www.mereobiopharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees33

Key executives

NameTitlePayExercisedYear born
Dr. Denise Vera Scots-Knight Ph.D.Co-Founder, CEO & Executive Director890.56kN/A1959
Mr. Charles Edward SermonCo-Founder, General Counsel, Business Development & Company Secretary625.79kN/A1969
Ms. Christine Fox CPAChief Financial Officer569.77kN/A1981
Dr. John P. Richard M.B.A.Co-Founder & Chief Business OfficerN/AN/A1957
Dr. John A. Lewicki Ph.D.Chief Scientific OfficerN/AN/A1952
Dr. Jackie ParkinSenior VP & Therapeutic HeadN/AN/A1958
Ms. Alexandra Hughes-WilsonChief of Patient Access & Commercial PlanningN/AN/A1971
Dr. Suba KrishnanSenior Vice President of Clinical DevelopmentN/AN/A1965
Mr. Bo KaraSenior VP and Head of Pharmaceutical Development & CMCN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Corporate governance

Mereo BioPharma Group plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.